Novocol Pharmaceutical Recalls Carbocaine 3% Mepivacaine HCl Due to Defective Cartridges
Novocol Pharmaceutical of Canada, Inc. initiated a Class II recall of Carbocaine 3% (mepivacaine hydrochloride) due to cracked cartridges. This voluntary action impacts U.S. nationwide supply, posing risks to patient safety and supply chain stability for dental practitioners. Procurement and regulatory teams must assess immediate inventory and long-term sourcing strategies.
FDA Class II Recall: Defective Carbocaine 3% Cartridges Identified
Novocol Pharmaceutical of Canada, Inc. has initiated a voluntary Class II recall, designated D-0233-2026, for its Cook-Walte, Carbocaine 3% (30 mg/mL) (mepivacaine hydrochloride Injection, USP). This critical action, commenced on October 31, 2025, stems from a significant product quality issue: defective containers, specifically cracked or broken cartridges. The affected product, packaged in cartons containing 50 Single-Dose Cartridges of 1.7 mL each, carries NDC 0362-0753-05. The recall specifically targets Lot D05159I, which has an expiration date of July 31, 2027. The distribution pattern for this recalled lot is U.S.A. Nationwide, indicating broad market exposure. For procurement directors and supply chain VPs, this means an immediate assessment of inventory is paramount to identify and quarantine any affected stock. The presence of cracked cartridges for mepivacaine hydrochloride, a critical local anesthetic, introduces risks of product leakage, potential contamination, and inaccurate dosing, directly impacting patient safety and the efficacy of dental procedures. Regulatory affairs heads must note the Class II classification, which signifies that use of the defective product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. However, the commercial implications of compromised product integrity are substantial.
Supply Chain Exposure: Implications for Mepivacaine Hydrochloride Procurement
The recall of Novocol Pharmaceutical of Canada, Inc.'s Carbocaine 3% (mepivacaine hydrochloride) due to defective cartridges presents a direct challenge to procurement and supply chain resilience within the dental and pharmaceutical sectors. While specific market share data for Novocol's mepivacaine hydrochloride products are not detailed in the available intelligence, its nationwide distribution across the U.S.A. suggests a significant footprint among dental practitioners and clinics. Procurement directors must immediately audit their current stock of Lot D05159I to prevent its use and initiate return procedures. The disruption in the supply of a widely used local anesthetic like mepivacaine hydrochloride necessitates swift action to secure alternative sources, minimizing potential delays in patient care and maintaining operational continuity for dental practices. Business development executives should monitor how this event might shift market dynamics, as competitors offering alternative mepivacaine hydrochloride or other local anesthetics may see increased demand. The integrity of pharmaceutical packaging is a fundamental aspect of product quality, and its failure can erode trust and necessitate costly supply chain adjustments.
Remediation Timeline and Future Regulatory Outlook
The recall initiated by Novocol Pharmaceutical of Canada, Inc. on October 31, 2025, remains classified as "Ongoing" by the FDA, as reported on December 24, 2025. This "Ongoing" status indicates that Novocol is actively engaged in removing the affected Cook-Walte, Carbocaine 3% (mepivacaine hydrochloride) product from distribution channels and addressing the root cause of the defective cartridges. Regulatory affairs heads should closely monitor the FDA's updates regarding this recall, as the firm's corrective and preventive actions (CAPA) will be under scrutiny. The effectiveness of Novocol's remediation efforts will dictate the timeline for resolution and could influence future regulatory interactions. While this is a voluntary, firm-initiated recall, the FDA maintains oversight to ensure public health is protected and that manufacturing processes are brought into compliance. A prolonged "Ongoing" status could signal challenges in identifying or rectifying the underlying manufacturing or quality control issues. Procurement teams should factor this uncertainty into their long-term sourcing strategies for mepivacaine hydrochloride, considering the potential for extended supply disruptions or increased regulatory scrutiny on Novocol Pharmaceutical of Canada, Inc. in the future.